RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial.   In a Phase 3 study, the ...

Influenza has killed 235 Albertans in the last 10 months, the most deaths since 2009. The CBC's Jennifer Lee looks at some ...

Influenza hemagglutinin subunit vaccines are more effective and offer better cross protection against various influenza virus ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

When the seasonal flu strikes, most people expect the familiar lineup of fever, aches and congestion. But for many patients, dizziness emerges as an ...

A long-lasting formulation of an antiviral drug greatly reduced people’s risk of a symptomatic flu infection in a trial, and ...

Moderna's messenger RNA flu vaccine candidate has shown has shown positive results in a late-stage trial. The biotechnology company said Monday its seasonal influenza vaccine candidate, mRNA-1010, ...

Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major ...

While respiratory illnesses such as flu and cough affect Ugandans year-round, researchers have identified specific months ...

Taking aim at a longtime target of anti-vaccine activists, CDC advisors said Thursday that the U.S. should not administer ...

The Advisory Committee on Immunization Practices (ACIP), recently remade by Health and Human Services Secretary Robert F.